Dual Anta-Inhibitors Targeting Protein Kinase CK1 and A_2A Adenosine Receptor Useful in Neurodegenerative Disorders

Currently, the number of patients with neurodegenerative pathologies is estimated at over one million, with consequences also on the economic level. Several factors contribute to their development, including overexpression of A(2A) adenosine receptors (A(2A)AR) in microglial cells and up-regulation and post-translational alterations of some casein kinases (CK), among them, CK-1 delta. The aim of the work was to study the activity of A(2A)AR and CK1 delta in neurodegeneration using in-house synthesized A(2A)/CK1 delta dual anta-inhibitors and to evaluate their intestinal absorption. Experiments were performed on N13 microglial cells, which were treated with a proinflammatory CK cocktail to simulate an inflammatory state typical of neurodegenerative diseases. Results showed that the dual anta-inhibitors have the ability to counteract the inflammatory state, even if compound 2 is more active than compound 1. In addition, compound 2 displayed an important antioxidant effect similar to the reference compound ZM241385. Since many known kinase inhibitors are very often unable to cross lipid bilayer membranes, the ability of A(2A)/CK1 delta double anta-inhibitors to cross the intestinal barrier was investigated by an everted gut sac assay. HPLC analysis revealed that both compounds are able to cross the intestinal barrier, making them promising candidates for oral therapy.